Jeffrey Mogil to Speak on Animal Models of Pain at Arrowhead’s 4th Annual Pain Therapeutics Summit

Share Article

Jeffrey Mogil, an internationally-renowned leader in pain research, will be presenting “What’s Wrong with Animal Models of Pain?” at Arrowhead’s upcoming 4th Annual Pain Therapeutics Summit, to be held October 4-5, 2010 in Philadelphia, Pennsylvania.

Jeffrey Mogil, an internationally-renowned leader in pain research, will be presenting “What’s Wrong with Animal Models of Pain?” at Arrowhead’s upcoming 4th Annual Pain Therapeutics Summit, to be held October 4-5, 2010 in Philadelphia, Pennsylvania.

Recent decades have seen an explosion in our understanding of the molecular and cellular underpinnings of pain, but virtually none of this knowledge has resulted in new clinical therapies. Many pain researchers believe that the problem may lie in the existing animal models of pain, which are reliable but much more complex and subtle than is commonly realized, and of questionable clinical relevance.

In addition to the disconnect between clinical symptoms and animal measures, there is a disconnect between the clinical epidemiology of pain and the types of pain being modeled in animals. Dr. Mogil’s presentation, “What’s Wrong with Animal Models of Pain?” will cover recent successes in his laboratory, involving migraine, vestibulodynia, and the development of a facial expression-based pain scale for the mouse (recently published in Nature Methods).

Jeffrey Mogil is currently the E.P. Taylor Professor of Pain Studies and the Canada Research Chair in the Genetics of Pain at McGill University. Dr. Mogil is the author of many major reviews of the subject and is the editor of The Genetics of Pain. He is a recognized authority in the fields of sex differences in pain and analgesia, and pain testing methods in the laboratory mouse. Dr. Mogil is the author of over 150 journal articles and book chapters since 1992, and has given over 190 invited lectures in that same period. He currently serves as a Section Editor (Neurobiology) at the journal Pain.

Now in its 4th year, Arrowhead’s Annual Pain Therapeutics Summit continues to attract both academic and industry leaders from around the globe to discuss pain management, preclinical and clinical development of new pain therapeutics, regulatory issues, commercialization of new pain therapies and various other topics integral to the field of pain therapeutics. For more information, go to http://www.paintherapeuticssummit.com or email us at enquires(at)paintherapeuticsummit(dot)com.

###

Share article on social media or email:

View article via:

Pdf Print